{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:09:40Z","timestamp":1785276580941,"version":"3.55.0"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease. The impacts of antihypertensive drugs and blood pressure (BP) on ALS are currently debatable.<\/jats:p><jats:p>\n          Objective\u2003To evaluate the causal relationship involving antihypertensive drugs, BP, and ALS through a Mendelian randomization (MR) analysis.<\/jats:p><jats:p>\n          Methods\u2003The causal relationship between BP and ALS was evaluated by a bidirectional two-sample MR analysis. Then, a sensitivity analysis was performed using a secondary BP genome-wide association study. The drug-target MR was employed to evaluate the impact of antihypertensive drugs on ALS. Furthermore, we used cis-expression quantitative trait loci (cis-eQTLs) data from brain tissue and blood to validate the positive results by a summary-based MR method.<\/jats:p><jats:p>\n          Results\u2003We found that an increment in systolic BP (SBP) could elevate the risk of ALS (inverse-variance weighted [IVW] odds ratio [OR]\u2009=\u20091.003; 95% confidence interval [95%CI]: 1.001\u20131.006; per 10-mmHg increment) and ALS might be protected by angiotensin-converting enzyme inhibitors (ACEIs; OR\u2009=\u20090.970; 95%CI: 0.956\u20130.984; p\u2009=\u20091.96\u2009\u00d7\u200910\u22125; per 10-mmHg decrement). A causal relationship was not observed between diastolic BP and other antihypertensive drugs in ALS.<\/jats:p><jats:p>\n          Conclusion\u2003In the present study, genetic support for elevated SBP serves as a risk factor for ALS. Besides, ACEIs hold promise as a candidate for ALS.<\/jats:p>","DOI":"10.1055\/s-0045-1804922","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:42:39Z","timestamp":1747179759000},"page":"001-008","source":"Crossref","is-referenced-by-count":1,"title":["Association among blood pressure, antihypertensive drugs, and amyotrophic lateral sclerosis"],"prefix":"10.1055","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-1327","authenticated-orcid":false,"given":"Zhiguang","family":"Li","sequence":"additional","affiliation":[{"name":"Xingtai Central Hospital, Department of Neurology, Xingtai Hebei, People's Republic of China."},{"name":"Xingtai Medical College, Department of Basic Medicine, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7787-8645","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Xingtai Central Hospital, Department of Neurology, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6075-7329","authenticated-orcid":false,"given":"Jiankai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Xingtai Central Hospital, Department of Neurology, Xingtai Hebei, People's Republic of China."},{"name":"Xingtai Medical College, Department of Basic Medicine, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3980-3672","authenticated-orcid":false,"given":"Feifei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xingtai Medical College, Department of Basic Medicine, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5435-9606","authenticated-orcid":false,"given":"Wei","family":"Dang","sequence":"additional","affiliation":[{"name":"Xingtai Medical College, Department of Basic Medicine, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8883-5913","authenticated-orcid":false,"given":"Yanan","family":"Jia","sequence":"additional","affiliation":[{"name":"Xingtai Central Hospital, Department of Science and Education, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4517-797X","authenticated-orcid":false,"given":"Fei","family":"Guo","sequence":"additional","affiliation":[{"name":"Xingtai Medical College, Department of Basic Medicine, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8329-9084","authenticated-orcid":false,"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[{"name":"Xingtai Medical College, Department of Basic Medicine, Xingtai Hebei, People's Republic of China."},{"name":"Xingtai Central Hospital, Department of Cardiac Surgery, Xingtai Hebei, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"E L Feldman","year":"2022","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"G BDRF Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1111\/ene.14940","article-title":"Prevalence of multimorbidity and its impact on survival in people with motor neuron disease","volume":"28","author":"S A Glasmacher","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2021.12.021","article-title":"Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review","volume":"96","author":"K Xu","year":"2022","journal-title":"J Clin Neurosci"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/17482968.2011.610110","article-title":"Modifying effect of arterial hypertension on amyotrophic lateral sclerosis","volume":"13","author":"C Moreau","year":"2012","journal-title":"Amyotroph Lateral Scler"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fneur.2016.00047","article-title":"Antecedent disease and amyotrophic lateral sclerosis: What is protecting whom?","volume":"7","author":"S K Hollinger","year":"2016","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jocn.2019.05.036","article-title":"Environmental risk factors and amyotrophic lateral sclerosis (ALS): A case-control study of ALS in China","volume":"66","author":"L Lian","year":"2019","journal-title":"J Clin Neurosci"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaneurol.2014.3367","article-title":"Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study","volume":"72","author":"F C Lin","year":"2015","journal-title":"JAMA Neurol"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000526982","article-title":"Cardiovascular diseases, medications, and ALS: a population-based case-control study","volume":"56","author":"H S Abdel Magid","year":"2022","journal-title":"Neuroepidemiology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/21678421.2019.1682613","article-title":"Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs","volume":"21","author":"R M Pfeiffer","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1007\/s10072-022-06131-7","article-title":"Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"43","author":"N Hu","year":"2022","journal-title":"Neurol Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/21678421.2016.1143515","article-title":"Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association","volume":"17","author":"C Franchi","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"N M Davies","year":"2018","journal-title":"BMJ"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3945\/ajcn.115.118216","article-title":"Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies","volume":"103","author":"P C Haycock","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"A F Schmidt","year":"2020","journal-title":"Nat Commun"},{"issue":"04","key":"ref16","first-page":"CD001841","article-title":"First-line drugs for hypertension","volume":"4","author":"J M Wright","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"ref17","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement","volume":"326","author":"V W Skrivankova","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits","volume":"50","author":"E Evangelou","year":"2018","journal-title":"Nat Genet"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.118.038814","article-title":"Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects","volume":"140","author":"D Gill","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s00125-020-05243-z","article-title":"Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study","volume":"63","author":"S Luo","year":"2020","journal-title":"Diabetologia"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jamapsychiatry.2021.0005","article-title":"Association of antihypertensive drug target genes with psychiatric disorders: A Mendelian randomization study","volume":"78","author":"S Chauquet","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41588-022-01154-4","article-title":"Genetic control of RNA splicing and its distinct role in complex trait variation","volume":"54","author":"T Qi","year":"2022","journal-title":"Nat Genet"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","article-title":"Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology","volume":"53","author":"W van Rheenen","year":"2021","journal-title":"Nat Genet"},{"issue":"06","key":"ref25","first-page":"1961","article-title":"Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic","volume":"45","author":"J Bowden","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ene.13620","article-title":"Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis","volume":"25","author":"J Mandrioli","year":"2018","journal-title":"Eur J Neurol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/jnr.23777","article-title":"Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease","volume":"95","author":"M A Daulatzai","year":"2017","journal-title":"J Neurosci Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"101612","DOI":"10.1016\/j.arr.2022.101612","article-title":"Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future","volume":"77","author":"F Gouveia","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.sjbs.2020.01.026","article-title":"Role of brain renin angiotensin system in neurodegeneration: An update","volume":"27","author":"O A Abiodun","year":"2020","journal-title":"Saudi J Biol Sci"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"P Masrori","year":"2020","journal-title":"Eur J Neurol"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1096\/fj.11-182873","article-title":"Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease","volume":"25","author":"Y F Dong","year":"2011","journal-title":"FASEB J"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"B W Kunkle","year":"2019","journal-title":"Nat Genet"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.biopsych.2022.11.002","article-title":"Prioritization of drug targets for neurodegenerative diseases by integrating genetic and proteomic data from brain and blood","volume":"93","author":"Y J Ge","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1007\/s12035-015-9584-5","article-title":"Angiotensin receptor blockade modulates NF\u03baB and STAT3 signaling and inhibits glial activation and neuroinflammation better than angiotensin-converting enzyme inhibition","volume":"53","author":"S A Bhat","year":"2016","journal-title":"Mol Neurobiol"},{"key":"ref35","author":"K Asraf","year":"2018"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(99)00211-3","article-title":"Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats","volume":"373","author":"A Ravati","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"03","key":"ref37","first-page":"367","article-title":"Neuroprotective effect of ACE inhibitors in glutamate - induced neurotoxicity: rat neuron culture study","volume":"21","author":"G Sengul","year":"2011","journal-title":"Turk Neurosurg"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/21678421.2012.745570","article-title":"Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis","volume":"14","author":"D Michal Freedman","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1804922.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:42:46Z","timestamp":1747179766000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1804922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":37,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,5,9]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["s00451804922"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1804922","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}